- Home
- STTK vs SYT Comparison
STTK vs SYT Comparison
Compare STTK & SYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SYT
- Stock Information
- Founded
- STTK 2016
- SYT 2010
- Country
- STTK United States
- SYT Japan
- Employees
- STTK N/A
- SYT N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SYT Real Estate
- Sector
- STTK Health Care
- SYT Finance
- Exchange
- STTK Nasdaq
- SYT Nasdaq
- Market Cap
- STTK 37.6M
- SYT 41.2M
- IPO Year
- STTK 2020
- SYT 2023
- Fundamental
- Price
- STTK $0.91
- SYT $2.00
- Analyst Decision
- STTK Hold
- SYT
- Analyst Count
- STTK 4
- SYT 0
- Target Price
- STTK $3.00
- SYT N/A
- AVG Volume (30 Days)
- STTK 108.4K
- SYT 7.9K
- Earning Date
- STTK 05-01-2025
- SYT 05-20-2025
- Dividend Yield
- STTK N/A
- SYT 0.30%
- EPS Growth
- STTK N/A
- SYT 63.72
- EPS
- STTK N/A
- SYT 0.23
- Revenue
- STTK $4,606,000.00
- SYT $196,361,934.00
- Revenue This Year
- STTK N/A
- SYT N/A
- Revenue Next Year
- STTK N/A
- SYT N/A
- P/E Ratio
- STTK N/A
- SYT $9.20
- Revenue Growth
- STTK 69.65
- SYT 35.74
- 52 Week Low
- STTK $0.69
- SYT $1.18
- 52 Week High
- STTK $11.76
- SYT $3.87
- Technical
- Relative Strength Index (RSI)
- STTK 47.64
- SYT 43.12
- Support Level
- STTK $0.84
- SYT $1.60
- Resistance Level
- STTK $1.00
- SYT $2.17
- Average True Range (ATR)
- STTK 0.09
- SYT 0.20
- MACD
- STTK 0.01
- SYT -0.05
- Stochastic Oscillator
- STTK 42.02
- SYT 44.49
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SYT SYLA Technologies Co. Ltd.
SYLA Technologies Co Ltd is a property technology company. It provides asset management platform systems that facilitate real estate crowd-funding as well as the purchase and sale of real estate.